Report post

Who is Dragonfly Therapeutics?

WALTHAM, Mass., March 5, 2024 /CNW/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET ®.

Is Dragonfly energy a good Biotech stock under $20?

Dragonfly Energy has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Dragonfly Energy has only been the subject of 3 research reports in the past 90 days. If you're on the hunt for a great biotech stock under $20... you need to see this video.

Is Dragonfly listed on the NASDAQ?

Dragonfly has entered into a definitive business combination agreement with Chardan NexTech Acquisition 2 Corp. (Nasdaq: CNTQ); upon closing, the combined company will be listed on the Nasdaq under the new ticker DFLI.

The World's Leading Crypto Trading Platform

Get my welcome gifts